Form 8-K - Current report:
SEC Accession No. 0001641172-25-003329
Filing Date
2025-04-09
Accepted
2025-04-09 08:13:50
Documents
16
Period of Report
2025-04-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50731
2 ex10-1.htm EX-10.1 30227
3 ex99-1.htm EX-99.1 20679
  Complete submission text file 0001641172-25-003329.txt   336008

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cing-20250408.xsd EX-101.SCH 3781
5 XBRL DEFINITION FILE cing-20250408_def.xml EX-101.DEF 30042
6 XBRL LABEL FILE cing-20250408_lab.xml EX-101.LAB 36718
7 XBRL PRESENTATION FILE cing-20250408_pre.xml EX-101.PRE 27065
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5714
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 25823877
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)